Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
企業コードNXL
会社名Nexalin Technology Inc
上場日Sep 16, 2022
最高経営責任者「CEO」Mr. Mark White
従業員数6
証券種類Ordinary Share
決算期末Sep 16
本社所在地1776 Yorktown
都市HOUSTON
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号77056
電話番号18322600222
ウェブサイトhttps://nexalin.com
企業コードNXL
上場日Sep 16, 2022
最高経営責任者「CEO」Mr. Mark White
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし